The human body is elegantly designed to heal itself, utilizing the immune system as its defense against various pathogens. Triggered by immune response signals, the immune system attacks and kills organisms and substances that invade body systems and cause disease. However, the immune system sometimes needs help in identifying and killing some invaders.
Cancer presents a complex and perplexing problem for effective immune system response, because it finds ways to hide from the immune system or block the immune system’s ability to battle against the disease. An important part of the immune system is its ability to differentiate between normal cells in the body and invaders. This differentiation allows the immune system to attack the invading cells while leaving normal cells alone. To achieve this, the immune system uses molecules on certain immune cells that need to be activated or inactivated to trigger an immune response. However, cancer cells can sometimes use these checkpoints to deceive the immune system and avoid being attacked. Newly developed drugs, known as checkpoint inhibitors, have shown some success in cancer treatments. However, a combination of checkpoint inhibitors and specific T cell-stimulating therapeutic vaccines indicates a much higher degree of efficacy.
Heat Biologics (NASDAQ: HTBX) is at the vanguard of this shift in cancer treatments, developing novel therapeutic vaccines to activate the immune system against a wide range of cancers. When antigens enter the body, they stimulate the immune system to produce antibodies in response to these foreign substances. Heat Biologics exploits this natural process to elicit a powerful immune response against the disease target. The company’s therapeutic vaccines are based on heat shock protein gp-96, a protein that activates the immune system when cells die. This protein is attached to the cell by what’s called a KDEL leash. Heat Biologic’s vaccines remove this leash and cause cells to continuously secrete gp96 and its chaperoned antigens to activate the immune system.
Heat Biologics recently announced the latest results of its ongoing phase 2 clinical trial in combination with Bristol-Myers Squibb’s checkpoint inhibitor. Researchers reported a strong correlation between T cell activation, tumor reductions, and increased overall survival in the patients evaluated. Patients with a sustained immune response also exhibited substantial tumor reductions. It appears the combination of Heat Biologics’ vaccine and checkpoint inhibitors may become an attractive therapeutic approach treating cancers.
For more information, please visit www.HeatBio.com
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer